Untargeted Lipidomics in Fabry Disease of Urine Samples by Low-Resolution Flow Injection Mass Spectrometry (ESI(±)-LTQ MS). [PDF]
Foletto RA +8 more
europepmc +1 more source
Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease. [PDF]
Acampora, E. +11 more
core
Comparative Evaluation of AAV8 and AAV9 Gene Therapy in Fabry Knockout (<i>Gla</i><sup>-/y</sup>) and Symptomatic (G3S<sup>Tg/+</sup><i>Gla</i><sup>-/y</sup>) Murine Models. [PDF]
Chang FP +5 more
europepmc +1 more source
A case of cardiac involvement in Fabry disease caused by the p.D313Y variant of the GLA-gene. [PDF]
Schnieder AL +3 more
europepmc +1 more source
Czech nationwide screening for Fabry disease in patients on maintenance dialysis: a call for evaluation of population-enriched <i>GLA</i> gene variants of uncertain significance. [PDF]
Rychlík I +16 more
europepmc +1 more source
The relationship between multiple plasma biomarker levels and renal disease activity in Fabry disease. [PDF]
Ozcan SG +9 more
europepmc +1 more source
Epigenetic Mechanisms in Fabry Disease: A Thematic Analysis Linking Differential Methylation Profiles and Genetic Modifiers to Disease Phenotype. [PDF]
Singh J, Santosh P, Ramaswami U.
europepmc +1 more source
Perivascular spaces and basilar artery remodeling in Fabry disease-a dual vascular pathology. [PDF]
Roh J +6 more
europepmc +1 more source
Looking for Fabry, Finding More: LVH Screening Yields Unexpected Gaucher Diagnosis. [PDF]
Szczepara S +8 more
europepmc +1 more source
Progress and Challenges in the Treatment of Fabry Disease. [PDF]
Lenders M, Menke ER, Brand E.
europepmc +1 more source

